Next Vial Review
Semaglutide GLP-1 weight-loss telehealth · Independently scored 5.8/10
Best for: compounded semaglutide at $249.97/month
Next Vial falls below our bar on medical oversight. Read the breakdown below before you give it money.
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
An online marketplace that connects patients to licensed providers for compounded semaglutide and tirzepatide injections, microdose options included. It is LegitScript verified and names its dispensing pharmacy: Manifest Pharmacy in Greer, SC. There is no membership required, and one price covers the consultation, the medication and free shipping. It serves 49 states.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to Next Vial
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Next Vial at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $249.97/mo (Starting monthly rate for GLP-1 program; tirzepatide rate not published.)
- What's included
- Medication · Consult · Shipping
- Availability
- 49 states
- FDA status
- No FDA warning letter on record
How Next Vial scores
Six columns, each one computed from something Next Vial has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
3.0/10$249.97/month is 32% above the register median of $189 for compounded semaglutide.
Effectiveness25%
8.5/10Dispenses semaglutide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
3.0/10On the seller's own pages, no price appears until the medical intake is finished.
Trust & Safety15%
5.0/10does not name a dispensing pharmacy; withholds price until after the intake; publishes its state list. Our verification confidence is medium.
Accessibility10%
9.8/10Publishes coverage in 49 of 50 states.
Support10%
7.0/10The price covers medication, consult, shipping.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on Next Vial
Last checked July 2026- Re-read the price on file across 1 dose or plan tier
- Checked state coverage: all 50
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.
What signing up with Next Vial involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1Next Vial does not show a price until you have worked through its medical questionnaire. Budget for the fact that you cannot compare it against anything until you have handed over health information.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3Next Vial does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering medication, consult, shipping.
- Cheapest standing monthly prices on record: semaglutide $249.97. Membership fees, first-month rates and insured copays are excluded from those figures.
- Coverage is published for 49 of 50 states.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
GLP-1 medications Next Vial offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
Starting monthly rate for GLP-1 program; tirzepatide rate not published.
Check the price yourself before you pay
Every figure here was read off Next Vial's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Semaglutide at $249.97 a month, within the normal band around this register's $189 median for the same drug and form
- The monthly figure covers medication, consult, shipping
- Coverage is published for 49 states
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- No price appears until the medical intake is complete, so the cost cannot be compared before health information is submitted
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality
What Next Vial charges
Next Vial lists $249.97/month. That sits above the middle of the market, which puts the burden on whatever else is in the package.
- Compounded semaglutide — $249.97/month
The median standing price across the GLP-1 providers we track is about $169/month, so this is a premium, and a premium has to buy something. Check what is bundled before accepting it.
Direct Meds dispenses semaglutide and tirzepatide from $249/month, which makes it the honest comparison to run before committing here.
What Next Vial dispenses
Next Vial prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two best-evidenced weight-loss molecules currently on the market. The medication is compounded rather than dispensed as an approved pen. Compounding serves real clinical needs and is entirely lawful; what it is not is reviewed, and the cost difference reflects that.
What we could verify
On the record: it treats patients in all 50 states. We searched the federal warning-letter record for this operator and came back with nothing. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You are optimizing for the twelve-month total rather than the first bill — a flat-rate seller such as CoreAge Rx will usually win that arithmetic.
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- you need access regardless of where you live
Our read
Next Vial costs more than the middle of this market. If the extras it charges for are ones you would actually use, that is a defensible trade. If not, the same molecule is available for less.
The Bottom Line
Next Vial falls below our bar on medical oversight. Read the breakdown below before you give it money.
Before you pay Next Vial
Starting at $249.97/month. Check today's price, then book the free consultation.
Where Next Vial is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this Next Vial review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
See Next Vial's current pricing
Plans start at $249.97/month. The free consultation is where you learn whether you qualify, and what it costs today.